Overview

A key corporate objective is to identify and develop cancer vaccines having both therapeutic and commercial value. The AlphaVax VRP technology has, in numerous clinical settings involving a number of different disease types, demonstrated itself to be safe while providing the appropriate immune response. Our technology has also proven itself to be adaptable and flexible being amendable to a wide range of antigen types.

The product pipeline reflects the adaptability of the technology as well as the therapeutic and commercial potential.

To translate scientific discovery into commercial success requires combining great science with effective development and commercialization all while satisfying stringent regulatory requirements. Our highly experienced vaccine development team brings substantial collective experience in process development, analytical methods, regulatory affairs, compliance, technology transfer, and manufacturing to establish an extensive product pipeline.